Clinical trial Recruiting at 7 sites Interventional Ages 18 and up

Ma-Zi-Ren-Wan (MZRW) herbal treatment for constipation in cancer survivors

Official title: Herbal Formula Ma-Zi-Ren-Wan (MZRW) on Bowel Movement Function and Gut Microbiome Among Cancer Survivors With Constipation: A Double-blinded Randomized Controlled Trial (RELIEVE)

Run by Memorial Sloan Kettering Cancer Center · NCT07091084 · Data updated 2026-11-12

This will see if the herbal formula Ma-Zi-Ren-Wan (MZRW) helps relieve functional constipation in adult cancer survivors compared with a placebo.

More Constipation trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment70 (estimated)
SponsorMemorial Sloan Kettering Cancer Center
Academic / other
Drugs / interventionschemotherapy, immunotherapy, radiation
Locations7 sites (Basking Ridge, New Jersey and 6 other locations)
StatusRecruiting
StartedJuly 15, 2025
Main results expectedJuly 15, 2028
Study endsJuly 15, 2028
Registry record updatedMay 22, 2026
Trial IDNCT07091084 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adult cancer survivors (age ≥18) with functional constipation by Rome IV criteria who completed surgery/chemotherapy/radiotherapy/immunotherapy or investigational therapy at least one month ago and have a Karnofsky score of 60 or higher.

Probably not a fit

Patients with constipation from a mechanical bowel obstruction, those still receiving recent active cancer therapy within the past month, with Karnofsky <60, or whose symptoms do not meet Rome IV functional constipation criteria are unlikely to benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, placebo-controlled interventional study comparing the herbal formula Ma-Zi-Ren-Wan (MZRW) to a matched placebo in adult cancer survivors who meet Rome IV criteria for functional constipation. Participants must be at least 18 years old, have completed major cancer treatments at least one month prior (except stable hormone or targeted therapies), and have a Karnofsky score ≥ 60. The study measures bowel symptoms and will analyze changes in the gut microbiome to explore biological effects of MZRW. Study activities take place at three Memorial Sloan Kettering locations in New Jersey.

Why it matters

Potential benefit: If effective, MZRW could offer a tolerated herbal option to improve bowel frequency and stool consistency for cancer survivors with functional constipation.

How similar studies have gone: Small studies in non-cancer populations with functional constipation have suggested MZRW may improve bowel symptoms, but high-quality evidence is limited and its use in cancer survivors is relatively untested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 18 years or greater;
* A diagnosis of cancer with no restrictions placed on type of cancer or stage;
* Completed surgery, chemotherapy, immunotherapy, and/or radiotherapy, or an investigational therapy at least one month prior to study initiation. Patients on stable doses of hormone therapy or targeted therapies will not be excluded;
* Karnofsky functional score of ≥ 60;
* Cancer survivors who have met the Rome IV criteria (Table 3) of the symptoms of functional constipation which must include two or more of the following:

  * Straining more than 25% of defecations.
  * Lumpy or hard stools (7-point Bristol stool scale 1 or 2) more than 25% of defecations.
  * Sensation of incomplete evacuation more than one-fourth (25%) of defecations.
  * Sensation of anorectal obstruction/blockage more than one-fourth (25%) of defecations.
  * Manual maneuvers to facilitate more than one-fourth (25%) of defecations.
  * Fewer than three spontaneous bowel movements per week.
  * Loose stools are rarely present without the use of laxatives.
  * Insufficient criteria for irritable bowel syndrome.
* Patient should be able to understand and complete all study assessments on their own
* Patient should be able to understand and provide signed informed consent in English.

Table 3. Rome IV criteria for functional constipation FUNCTIONAL CONSTIPATION Diagnostic criteria\*

1. Must include two or more of the following:\*\*
2. Straining during more than ¼ (25%) of defecations
3. Lumpy or hard stools (Bristol Stool Form Scale 1-2) more than ¼ (25%) of defecations
4. Sensation of incomplete evacuation more than ¼ (25%) of defecations
5. Sensation of anorectal obstruction/blockage more than ¼ (25%) of defecations
6. Fewer than three SBM per week
7. Manual maneuvers to facilitate more than ¼ (25%) of defecations (e.g., digital evacuation, support of the pelvic floor)

9\. Loose stools are rarely present without the use of laxatives 9. Insufficient criteria for irritable bowel syndrome Note \*Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis

Exclusion Criteria:

* Patients who have allergic history to herbs or Chinese medicine;
* Clinically significant abnormal liver (2 times the ULN for ALT or AST) and kidney disfunction(eGFR below 59 mL/min/1.73m² ) from recent laboratory test recorded in the medical record (within 2 month);
* Patients who have any signs of bowel obstruction, or have high risk of bowel obstruction assessed by their treating physician, including factors such as tumor invasion into abdominal organs, recent abdominal surgery, and prior abdominal radiation therapy;
* Patients who are prescribed opioid antagonists including methylnaltrexone, naloxegol and naldemedine for opioid induced constipation and required not to stop the medication;
* Women who are pregnant, lactating, or not practicing proper contraception by patient report.Patient's should follow proper contraception guidelines for at least 30 days following last dose of the study drug.

Where it's running

  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
    Basking Ridge, New Jersey, United States
    Recruiting
  • Memorial Sloan Kettering Monmouth (All Protocol Activities)
    Middletown, New Jersey, United States
    Recruiting
  • Memorial Sloan Kettering Bergen (All Protocol Activities)
    Montvale, New Jersey, United States
    Recruiting
  • Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities)
    Commack, New York, United States
    Recruiting
  • Memorial Sloan Kettering Westchester (All Protocol Activities)
    Harrison, New York, United States
    Recruiting
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York, United States
    Recruiting
Show 1 more location
  • Memorial Sloan Kettering Nassau (All Protocol Activities)
    Rockville Centre, New York, United States
    Recruiting

Study contacts

  • Principal investigator: Jun Mao, MD, MSCE — Memorial Sloan Kettering Cancer Center
  • Study coordinator: Jun Mao, MD, MSCE
  • Email: maoj@mskcc.org
  • Phone: 646-608-8552

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.